Archived Editions (COVID-19 Genomics and Precision Public Health Weekly Update)

Published on 09/23/2021

COVID-19 Genomics and Precision Public Health Weekly Update Content

Pathogen and Human Genomics Studies

- Outcomes of SARS-CoV-2 infection in patients with cystic fibrosis: A multicenter retrospective research network study. (https://pubmed.ncbi.nlm.nih.gov/34520894)
  Hadi Yousaf B et al. Respiratory medicine 2021 9 106606

  Analysis of a multicenter research network TriNETX was performed including patients more than 16 years of age diagnosed with COVID-19. Outcomes in COVID-19 positive pwCF were compared with a propensity-matched cohort of people without CF. Following robust propensity matching, pwCF had higher hospitalization rate (RR 1.56, 95% CI 1.20-2.04), critical care need (RR 1.78, 95% CI 1.13-2.79), and acute renal injury (RR 1.60, 95% CI 1.07-2.39) as compared to patients without CF.

- High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape (https://www.nature.com/articles/s41586-021-04005-0)
  F Schmidt et al, Nature, September 20, 2021

  By aggregating VOC-associated and antibody-selected spike substitutions into a single polymutant spike protein, we show that 20 naturally occurring mutations in SARS-CoV-2 spike are sufficient to generate pseudotypes with near-complete resistance to the polyclonal neutralizing antibodies generated by convalescents or mRNA vaccine recipients. Strikingly, however, plasma from individuals who had been infected and subsequently received mRNA vaccination, neutralized pseudotypes bearing this highly resistant SARS-CoV-2 polymutant spike, or diverse sarbecovirus spike proteins. Thus, optimally elicited human polyclonal antibodies against SARS-CoV-2 should be resilient to

substantial future SARS-CoV-2 variation and may confer protection against potential future sarbecovirus pandemics.

- Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge (https://www.medrxiv.org/content/10.1101/2021.09.17.21263624v1)
  LR Baden et al, MEDRXIV, September 22, 2021
- Prior Covid-19 and high RBD-IgG levels correlate with protection against VOC-delta SARS-CoV-2 infection in vaccinated Nursing Home Residents (https://www.medrxiv.org/content/10.1101/2021.09.21.21263880v1)
  H BLain et al, MEDRXIV, September 21, 2021
- Absence of Excess Mortality in a Highly Vaccinated Population During the Initial Covid-19 Delta Period. (https://www.medrxiv.org/content/10.1101/2021.09.16.21263477v1)
  JS Faust et al, MEDRXIV, September 21, 2021
- Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses (https://www.medrxiv.org/content/10.1101/2021.09.17.21263532v1)
  A Tauzin et al, MEDRXIV, September 21, 2021
- Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern (https://www.nature.com/articles/s41467-021-25913-9)
  W Yang et al, Nature Comms, September 22, 2021

  To support COVID-19 pandemic planning, we develop a model-inference system to estimate epidemiological properties of new SARS-CoV-2 variants of concern using case and mortality data while accounting for under-ascertainment, disease seasonality, non-pharmaceutical interventions, and mass-vaccination. Applying this system to study three variants of concern, we estimate that B.1.1.7 has a 46.6% (95% CI: 32.3–54.6%) transmissibility increase but nominal immune escape from protection induced by prior wild-type infection; B.1.351 has a 32.4% (95% CI: 14.6–48.0%) transmissibility increase and 61.3% (95% CI: 42.6–85.8%) immune escape; and P.1 has a 43.3% (95% CI: 30.3–65.3%) transmissibility increase and 52.5% (95% CI: 0–75.8%) immune escape.

- Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. (https://pubmed.ncbi.nlm.nih.gov/34551224)
  Pilishvili Tamara et al. The New England journal of medicine 2021 9

  The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or =50 years), race and ethnic group, presence of underlying conditions, and level of patient contact.

- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. (https://pubmed.ncbi.nlm.nih.gov/34551225)
  El Sahly Hana M et al. The New England journal of medicine 2021 9

  > The trial enrolled 30,415 participants; 15,209 were assigned to receive the mRNA-1273 vaccine, and 15,206 to receive placebo. More than 96% of participants received both injections, 2.3% had evidence of SARS-CoV-2 infection at baseline, and the median follow-up was 5.3 months in the blinded phase. Vaccine efficacy in preventing Covid-19 illness was 93.2% (95% confidence interval [CI], 91.0 to 94.8), with 55 confirmed cases in the mRNA-1273 group (9.6 per 1000 person-years; 95% CI, 7.2 to 12.5) and 744 in the placebo group (136.6 per 1000 person-years; 95% CI, 127.0 to 146.8). The efficacy in preventing severe disease was 98.2% (95% CI, 92.8 to 99.6).

- Assessment of a Program for SARS-CoV-2 Screening and Environmental Monitoring in an Urban Public School District (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784428?resultClick=1)
  J Crowe et al, JAMA Network Open, September 22, 2021

  > In this quality improvement study, weekly school-based saliva polymerase chain reaction testing at 3 urban public schools was associated with increased case detection among staff and students compared with symptom-based strategies, exceeding county-level case rates. SARS-CoV-2 was detected in school wastewater samples each week as well as air and surface samples from choir classrooms.

Non-Genomics Precision Health Studies

- Outcomes of SARS-CoV-2 infection in patients with cystic fibrosis: A multicenter retrospective research network study. (https://pubmed.ncbi.nlm.nih.gov/34520894)
  Hadi Yousaf B et al. Respiratory medicine 2021 9 106606

  > Analysis of a multicenter research network TriNETX was performed including patients more than 16 years of age diagnosed with COVID-19. Outcomes in COVID-19 positive pwCF were compared with a propensity-matched cohort of people without CF. Following robust propensity matching, pwCF had higher hospitalization rate (RR 1.56, 95% CI 1.20-2.04), critical care need (RR 1.78, 95% CI 1.13-2.79), and acute renal injury (RR 1.60, 95% CI 1.07-2.39) as compared to patients without CF.

- High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape (https://www.nature.com/articles/s41586-021-04005-0)
  F Schmidt et al, Nature, September 20, 2021

  > By aggregating VOC-associated and antibody-selected spike substitutions into a single polymutant spike protein, we show that 20 naturally occurring mutations in SARS-CoV-2 spike are sufficient to generate pseudotypes with near-complete resistance to the polyclonal neutralizing antibodies generated by convalescents or mRNA vaccine recipients. Strikingly, however, plasma from individuals who had been infected and subsequently received mRNA vaccination, neutralized pseudotypes bearing this highly resistant SARS-CoV-2 polymutant spike, or diverse sarbecovirus spike proteins.

Thus, optimally elicited human polyclonal antibodies against SARS-CoV-2 should be resilient to substantial future SARS-CoV-2 variation and may confer protection against potential future sarbecovirus pandemics.

- Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge (https://www.medrxiv.org/content/10.1101/2021.09.17.21263624v1)
  LR Baden et al, MEDRXIV, September 22, 2021

- Prior Covid-19 and high RBD-IgG levels correlate with protection against VOC-delta SARS-CoV-2 infection in vaccinated Nursing Home Residents (https://www.medrxiv.org/content/10.1101/2021.09.21.21263880v1)
  H BLain et al, MEDRXIV, September 21, 2021

- Absence of Excess Mortality in a Highly Vaccinated Population During the Initial Covid-19 Delta Period. (https://www.medrxiv.org/content/10.1101/2021.09.16.21263477v1)
  JS Faust et al, MEDRXIV, September 21, 2021

- Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses (https://www.medrxiv.org/content/10.1101/2021.09.17.21263532v1)
  A Tauzin et al, MEDRXIV, September 21, 2021

- Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern (https://www.nature.com/articles/s41467-021-25913-9)
  W Yang et al, Nature Comms, September 22, 2021

  To support COVID-19 pandemic planning, we develop a model-inference system to estimate epidemiological properties of new SARS-CoV-2 variants of concern using case and mortality data while accounting for under-ascertainment, disease seasonality, non-pharmaceutical interventions, and mass-vaccination. Applying this system to study three variants of concern, we estimate that B.1.1.7 has a 46.6% (95% CI: 32.3–54.6%) transmissibility increase but nominal immune escape from protection induced by prior wild-type infection; B.1.351 has a 32.4% (95% CI: 14.6–48.0%) transmissibility increase and 61.3% (95% CI: 42.6–85.8%) immune escape; and P.1 has a 43.3% (95% CI: 30.3–65.3%) transmissibility increase and 52.5% (95% CI: 0–75.8%) immune escape.

- Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. (https://pubmed.ncbi.nlm.nih.gov/34551224)
  Pilishvili Tamara et al. The New England journal of medicine 2021 9

  The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3

to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or =50 years), race and ethnic group, presence of underlying conditions, and level of patient contact.

- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. (https://pubmed.ncbi.nlm.nih.gov/34551225)
  El Sahly Hana M et al. The New England journal of medicine 2021 9

  The trial enrolled 30,415 participants; 15,209 were assigned to receive the mRNA-1273 vaccine, and 15,206 to receive placebo. More than 96% of participants received both injections, 2.3% had evidence of SARS-CoV-2 infection at baseline, and the median follow-up was 5.3 months in the blinded phase. Vaccine efficacy in preventing Covid-19 illness was 93.2% (95% confidence interval [CI], 91.0 to 94.8), with 55 confirmed cases in the mRNA-1273 group (9.6 per 1000 person-years; 95% CI, 7.2 to 12.5) and 744 in the placebo group (136.6 per 1000 person-years; 95% CI, 127.0 to 146.8). The efficacy in preventing severe disease was 98.2% (95% CI, 92.8 to 99.6).
- Assessment of a Program for SARS-CoV-2 Screening and Environmental Monitoring in an Urban Public School District (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784428?resultClick=1)
  J Crowe et al, JAMA Network Open, September 22, 2021

  In this quality improvement study, weekly school-based saliva polymerase chain reaction testing at 3 urban public schools was associated with increased case detection among staff and students compared with symptom-based strategies, exceeding county-level case rates. SARS-CoV-2 was detected in school wastewater samples each week as well as air and surface samples from choir classrooms.

News, Reviews and Commentaries

- Outcomes of SARS-CoV-2 infection in patients with cystic fibrosis: A multicenter retrospective research network study. (https://pubmed.ncbi.nlm.nih.gov/34520894)
  Hadi Yousaf B et al. Respiratory medicine 2021 9 106606

  Analysis of a multicenter research network TriNETX was performed including patients more than 16 years of age diagnosed with COVID-19. Outcomes in COVID-19 positive pwCF were compared with a propensity-matched cohort of people without CF. Following robust propensity matching, pwCF had higher hospitalization rate (RR 1.56, 95% CI 1.20-2.04), critical care need (RR 1.78, 95% CI 1.13-2.79), and acute renal injury (RR 1.60, 95% CI 1.07-2.39) as compared to patients without CF.
- High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape (https://www.nature.com/articles/s41586-021-04005-0)
  F Schmidt et al, Nature, September 20, 2021

  By aggregating VOC-associated and antibody-selected spike substitutions into a single polymutant spike protein, we show that 20 naturally occurring mutations in SARS-CoV-2 spike are sufficient to

generate pseudotypes with near-complete resistance to the polyclonal neutralizing antibodies generated by convalescents or mRNA vaccine recipients. Strikingly, however, plasma from individuals who had been infected and subsequently received mRNA vaccination, neutralized pseudotypes bearing this highly resistant SARS-CoV-2 polymutant spike, or diverse sarbecovirus spike proteins. Thus, optimally elicited human polyclonal antibodies against SARS-CoV-2 should be resilient to substantial future SARS-CoV-2 variation and may confer protection against potential future sarbecovirus pandemics.

- Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge (https://www.medrxiv.org/content/10.1101/2021.09.17.21263624v1)
  LR Baden et al, MEDRXIV, September 22, 2021

- Prior Covid-19 and high RBD-IgG levels correlate with protection against VOC-delta SARS-CoV-2 infection in vaccinated Nursing Home Residents (https://www.medrxiv.org/content/10.1101/2021.09.21.21263880v1)
  H BLain et al, MEDRXIV, September 21, 2021

- Absence of Excess Mortality in a Highly Vaccinated Population During the Initial Covid-19 Delta Period. (https://www.medrxiv.org/content/10.1101/2021.09.16.21263477v1)
  JS Faust et al, MEDRXIV, September 21, 2021

- Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a sixteen-week interval between doses (https://www.medrxiv.org/content/10.1101/2021.09.17.21263532v1)
  A Tauzin et al, MEDRXIV, September 21, 2021

- Development of a model-inference system for estimating epidemiological characteristics of SARS-CoV-2 variants of concern (https://www.nature.com/articles/s41467-021-25913-9)
  W Yang et al, Nature Comms, September 22, 2021

  To support COVID-19 pandemic planning, we develop a model-inference system to estimate epidemiological properties of new SARS-CoV-2 variants of concern using case and mortality data while accounting for under-ascertainment, disease seasonality, non-pharmaceutical interventions, and mass-vaccination. Applying this system to study three variants of concern, we estimate that B.1.1.7 has a 46.6% (95% CI: 32.3–54.6%) transmissibility increase but nominal immune escape from protection induced by prior wild-type infection; B.1.351 has a 32.4% (95% CI: 14.6–48.0%) transmissibility increase and 61.3% (95% CI: 42.6–85.8%) immune escape; and P.1 has a 43.3% (95% CI: 30.3–65.3%) transmissibility increase and 52.5% (95% CI: 0–75.8%) immune escape.

- Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. (https://pubmed.ncbi.nlm.nih.gov/34551224)
  Pilishvili Tamara et al. The New England journal of medicine 2021 9

The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or =50 years), race and ethnic group, presence of underlying conditions, and level of patient contact.

- Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. (https://pubmed.ncbi.nlm.nih.gov/34551225)
  El Sahly Hana M et al. The New England journal of medicine 2021 9

  The trial enrolled 30,415 participants; 15,209 were assigned to receive the mRNA-1273 vaccine, and 15,206 to receive placebo. More than 96% of participants received both injections, 2.3% had evidence of SARS-CoV-2 infection at baseline, and the median follow-up was 5.3 months in the blinded phase. Vaccine efficacy in preventing Covid-19 illness was 93.2% (95% confidence interval [CI], 91.0 to 94.8), with 55 confirmed cases in the mRNA-1273 group (9.6 per 1000 person-years; 95% CI, 7.2 to 12.5) and 744 in the placebo group (136.6 per 1000 person-years; 95% CI, 127.0 to 146.8). The efficacy in preventing severe disease was 98.2% (95% CI, 92.8 to 99.6).
- Assessment of a Program for SARS-CoV-2 Screening and Environmental Monitoring in an Urban Public School District (https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784428?resultClick=1)
  J Crowe et al, JAMA Network Open, September 22, 2021

  In this quality improvement study, weekly school-based saliva polymerase chain reaction testing at 3 urban public schools was associated with increased case detection among staff and students compared with symptom-based strategies, exceeding county-level case rates. SARS-CoV-2 was detected in school wastewater samples each week as well as air and surface samples from choir classrooms.

Page last reviewed: Oct 1, 2020

Page last updated: Sep 27, 2021

Content source: Office of Genomics and Precision Public Health (http://www.cdc.gov/genomics/), CDC Office of Science (https://www.cdc.gov/od/science/index.htm)